1,092 results

#213941-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe3_ChR2_mCherry (#213941). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the PV+ basket cell-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#50465-AAV2.T

Ready-to-use AAV2 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 31, 2019

Academic Institutions and Nonprofits only

#121675-AAV5

Ready-to-use AAV5 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Sept. 27, 2024

Academic Institutions and Nonprofits only

#111068-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-dLight1.2 (#111068). In addition to the viral particles, you will also receive purified pAAV-hSyn-dLight1.2 plasmid DNA. Synapsin-driven expression of dLight1.2 dopamine sensor. This sensor has a slightly increased dynamic range and is better for 2P imaging in vivo. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Feb. 25, 2021

Academic Institutions and Nonprofits only

#213939-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_GCaMP6f (#213939). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#111067-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-dLight1.1 (#111067). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.1 plasmid DNA. CAG-driven expression of dLight1.1 dopamine sensor. This sensor is recommended for photometry in vivo. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

March 12, 2021

Academic Institutions and Nonprofits only

#105554-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.CAG.tdTomato.WPRE.SV40 (#105554). In addition to the viral particles, you will also receive purified pENN.AAV.CAG.tdTomato.WPRE.SV40 plasmid DNA. CAG-driven tdTomato expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 7, 2018

Academic Institutions and Nonprofits only

#83899-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

June 1, 2020

Academic Institutions and Nonprofits only

#100054-AAV9

Ready-to-use AAV9 particles produced from pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (#100054). In addition to the viral particles, you will also receive purified pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 plasmid DNA. CAG-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 14, 2018

Academic Institutions and Nonprofits only

#114472-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-mCherry (#114472). In addition to the viral particles, you will also receive purified pAAV-hSyn-mCherry plasmid DNA. Synapsin-driven mCherry control vector. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

March 2, 2020

Academic Institutions and Nonprofits only